Adjunctive vitamin D for the treatment of active juvenile idiopathic arthritis: An open‑label, prospective, randomized controlled trial

  • Authors:
    • Tao Tang
    • Yu Zhang
    • Chong Luo
    • Mingyue Liu
    • Li Xu
    • Xuemei Tang
  • View Affiliations

  • Published online on: October 25, 2019     https://doi.org/10.3892/etm.2019.8133
  • Pages: 4921-4926
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vitamin D has an important immunomodulatory effect, but no trial has examined the effect of boosting serum levels of 25‑hydroxyvitamin D (25OHD) in individuals with juvenile idiopathic arthritis (JIA). The aim of the present study was to assess whether vitamin D supplementation reduced disease activity and adjusted/maintained bone mass in patients with active JIA. A 24‑week randomized trial was undertaken at Children's Hospital of Chongqing Medical University. Treatment‑naive patients with JIA were randomly assigned (1:1) to one of two groups: Standard treatment with high dose oral cholecalciferol [2,000 IU per day; experimental group (EG)] or without supplementation [control group (CG)]. The primary outcomes were the 27‑joint Juvenile Arthritis Disease Activity Score (JADAS‑27 score), the Z‑score for bone mineral density (BMD), and serum levels of 25OHD. A per‑protocol analysis set approach was used. The Mann‑Whitney U test was the main tool used for data analysis. A total of 42 participants were assigned randomly to the EG (n=20) or the CG (n=22); of these, 36 (n=18 and n=18, respectively) were included in per‑protocol analysis. After 24 weeks, the mean level of 25OHD in the EG was higher than that in the CG (P<0.05). At the end of the intervention, there were no clear differences between the two groups in terms of BMD or JADAS‑27 score (both P>0.05). Cholecalciferol supplementation (2000 IU/day) for 24 weeks raised serum levels of 25OHD in JIA patients but did not reduce disease activity or improve BMD (registration no. ChiCTR‑INR‑16009235; Date of Registration: 2016‑10‑12).

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tang, T., Zhang, Y., Luo, C., Liu, M., Xu, L., & Tang, X. (2019). Adjunctive vitamin D for the treatment of active juvenile idiopathic arthritis: An open‑label, prospective, randomized controlled trial. Experimental and Therapeutic Medicine, 18, 4921-4926. https://doi.org/10.3892/etm.2019.8133
MLA
Tang, T., Zhang, Y., Luo, C., Liu, M., Xu, L., Tang, X."Adjunctive vitamin D for the treatment of active juvenile idiopathic arthritis: An open‑label, prospective, randomized controlled trial". Experimental and Therapeutic Medicine 18.6 (2019): 4921-4926.
Chicago
Tang, T., Zhang, Y., Luo, C., Liu, M., Xu, L., Tang, X."Adjunctive vitamin D for the treatment of active juvenile idiopathic arthritis: An open‑label, prospective, randomized controlled trial". Experimental and Therapeutic Medicine 18, no. 6 (2019): 4921-4926. https://doi.org/10.3892/etm.2019.8133